Home / BCLI : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does BCLI make money? Does BCLI have pricing power? What's the Earnings Whisper? Will BCLI profit more as the business scales? What is BCLI's management track record? Is BCLI's current price justified?

Brainstorm Cell Therapeutics Inc.

$1.08 +$0.47 (+77.05%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$1.03

Day Range

$1.02$1.08

Year Range

$0.46$1.69

Market Cap

11.92M

AVG Volume

23.77K

Trailing/Forward PE

-1.14/-

PEG ratio

-0.09

Dividend Yield

Next Earnings Date

2026-11-16

Primary Exchange

Other OTC

Revenue (USD) · TTM

BCLI Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	0
26 Q1	0
25 Q4	0
25 Q3	0
25 Q2	0
25 Q1	0
24 Q4	0
24 Q3	343K
24 Q2	343K
24 Q1	343K

Net Income (USD) · TTM

BCLI Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-10.52M
26 Q1	-9.57M
25 Q4	-10.31M
25 Q3	-10.85M
25 Q2	-11.45M
25 Q1	-11.09M
24 Q4	-11.62M
24 Q3	-14.23M
24 Q2	-12.75M
24 Q1	-15.53M

Operating Income (USD) · TTM

BCLI Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-9.95M
26 Q1	-8.91M
25 Q4	-9.95M
25 Q3	-10.9M
25 Q2	-11.9M
25 Q1	-12.31M
24 Q4	-11.69M
24 Q3	-13.31M
24 Q2	-16.3M
24 Q1	-18.76M

EBITDA (USD) · TTM

BCLI EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-9.77M
26 Q1	-8.73M
25 Q4	-9.75M
25 Q3	-10.69M
25 Q2	-11.68M
25 Q1	-12.08M
24 Q4	-11.45M
24 Q3	-13.83M
24 Q2	-16.81M
24 Q1	-19.27M

Cash Flows (USD) · TTM

BCLI Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-4.06M
26 Q1	-6.66M
25 Q4	-6.97M
25 Q3	-7.28M
25 Q2	-9.48M
25 Q1	-7.66M
24 Q4	-9.09M
24 Q3	-11.33M
24 Q2	-14.46M
24 Q1	-19.55M

EPS (USD) · TTM

BCLI EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-0.95
26 Q1	-0.94
25 Q4	-1.2
25 Q3	-1.5
25 Q2	-1.82
25 Q1	-2.02
24 Q4	-2.36
24 Q3	-3.5
24 Q2	-3.41
24 Q1	-4.82

Expenses (USD) · TTM

BCLI Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	-86K
26 Q1	-1.08M
25 Q4	0
25 Q3	10.9M
25 Q2	11.9M
25 Q1	12.31M
24 Q4	11.63M
24 Q3	13.24M
24 Q2	16.25M
24 Q1	18.72M

Shares Outstanding (USD) · TTM

BCLI Shares Outstanding (USD) · TTM by quarter
Period	Shares Outstanding (USD) · TTM
26 Q2	-2.68M
26 Q1	-936K
25 Q4	-1.52M
25 Q3	-1.58M
25 Q2	-1.61M
25 Q1	-1.3M
24 Q4	-750K
24 Q3	-542K
24 Q2	-912K
24 Q1	-1.71M

Employee Count

BCLI Employee Count by quarter
Period	Employee Count
2025	20
2024	29
2023	29
2022	41
2021	43
2020	40
2019	32
2018	31
2017	24
2016	22

Free Cash Flow Yield

BCLI Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-34.04%
Sep 26	-35.01%
Aug 26	-32.83%
Aug 26	-37.52%
Aug 26	-37.14%
Aug 26	-76.68%
Jul 26	-67.1%
Jul 26	-62.91%
Jul 26	-67.39%
Jul 26	-55.92%
Jul 26	-41.94%
Jun 26	-64.94%
Jun 26	-69.86%
Jun 26	-80.51%
Jun 26	-80.67%
May 26	-80.52%
May 26	-88.8%
May 26	-87.52%
May 26	-108.34%
May 26	-114.46%
Apr 26	-97.73%
Apr 26	-89.36%
Apr 26	-81.53%
Apr 26	-83.61%
Mar 26	-73.68%
Mar 26	-78.48%
Mar 26	-88.21%
Mar 26	-93.18%
Feb 26	-94.58%
Feb 26	-108.46%
Feb 26	-124.83%
Feb 26	-114.07%
Jan 26	-105.02%
Jan 26	-110.27%
Jan 26	-112.14%
Jan 26	-122.52%
Jan 26	-108.46%
Dec 25	-98.75%
Dec 25	-118.14%
Dec 25	-118.14%
Dec 25	-110.27%
Nov 25	-103.38%
Nov 25	-103.38%
Nov 25	-108.46%
Nov 25	-164.14%
Oct 25	-169.19%
Oct 25	-154.89%
Oct 25	-169.19%
Oct 25	-159.38%
Oct 25	-152.74%
Sep 25	-154.89%
Sep 25	-157.1%
Sep 25	-157.1%
Sep 25	-154.89%
Aug 25	-144.7%
Aug 25	-169.19%
Aug 25	-174.56%
Aug 25	-208.27%
Aug 25	-180.3%
Jul 25	-167.77%
Jul 25	-143.81%
Jul 25	-100.66%
Jul 25	-104.14%
Jun 25	-113.96%
Jun 25	-99.01%
Jun 25	-109.82%
Jun 25	-99.01%
May 25	-107.86%
May 25	-111.85%
May 25	-91.51%
May 25	-135%
May 25	-126.43%
Apr 25	-163.39%
Apr 25	-181.85%
Apr 25	-208.95%
Apr 25	-138.52%
Mar 25	-179.31%
Mar 25	-151.33%
Mar 25	-134.2%
Mar 25	-133.36%
Feb 25	-133.36%
Feb 25	-123.34%
Feb 25	-114.72%
Feb 25	-124.78%
Jan 25	-117.24%
Jan 25	-97.43%
Jan 25	-112.9%
Jan 25	-105.63%
Jan 25	-95.69%
Dec 24	-87.09%
Dec 24	-93.59%
Dec 24	-147.16%
Dec 24	-134.2%
Nov 24	-122.63%
Nov 24	-170.7%
Nov 24	-176.35%
Nov 24	-253.77%
Nov 24	-163.72%
Oct 24	-155.37%
Oct 24	-135.35%

Price to Sales

BCLI Price to Sales by quarter
Period	Price to Sales
Mar 25	18.42
Mar 25	21.83
Mar 25	24.61
Mar 25	24.77
Feb 25	24.77
Feb 25	26.78
Feb 25	28.79
Feb 25	26.47
Jan 25	28.17
Jan 25	33.9
Jan 25	29.26
Jan 25	31.27
Jan 25	34.52
Dec 24	37.93
Dec 24	35.3
Dec 24	22.45
Dec 24	24.61
Nov 24	26.94
Nov 24	19.35
Nov 24	18.73
Nov 24	16.61
Nov 24	25.75
Oct 24	27.13
Oct 24	31.14
Oct 24	27.68
Oct 24	32.25
Sep 24	46.23
Sep 24	50.38
Sep 24	58.55
Sep 24	53.43
Aug 24	64.23
Aug 24	69.9
Aug 24	70.73
Aug 24	48.95
Aug 24	60.9
Jul 24	66.31
Jul 24	65.3
Jul 24	79.27
Jul 24	69.08
Jun 24	63.92
Jun 24	69.83
Jun 24	88.71
Jun 24	77.64
May 24	91.85
May 24	101.42
May 24	98.15
May 24	67.05
May 24	55.87
Apr 24	78.61
Apr 24	78.22
Apr 24	85.87
Apr 24	95.77
Oct 20	495.75
Oct 20	431.91
Sep 20	422.31
Sep 20	426.26
Sep 20	377.68
Sep 20	355.36
Aug 20	353.38
Aug 20	363.55
Aug 20	374.85
Aug 20	361.29
Jul 20	371.76
Jul 20	427.73
Jul 20	400.02
Jul 20	363.53
Jul 20	334.72
Jun 20	347.34
Jun 20	278.48
Jun 20	232.38
Jun 20	249.12
May 20	204.4
May 20	178.61
May 20	144.86
May 20	161.05
May 20	137.32
Apr 20	133.15
Apr 20	133.15
Apr 20	111.65
Apr 20	102
Mar 20	107.48
Mar 20	100.9
Mar 20	121.74
Mar 20	187.55
Feb 20	153.11
Feb 20	150.7
Feb 20	110.85
Feb 20	87.22
Jan 20	87.43
Jan 20	88.93
Jan 20	93.45
Jan 20	93.45
Jan 20	89.58
Dec 19	87.86
Dec 19	79.48
Dec 19	82.7
Dec 19	84.42
Nov 19	85.28
Nov 19	84.21
Nov 19	80.56

Price to Book

BCLI Price to Book by quarter
Period	Price to Book
Mar 23	40.75
Mar 23	42.33
Mar 23	42.59
Mar 23	54.95
Feb 23	59.68
Feb 23	61.79
Feb 23	76.77
Feb 23	70.99
Jan 23	39.96
Jan 23	39.96
Jan 23	38.39
Jan 23	41.28
Dec 22	43.12
Dec 22	44.7
Dec 22	50.48
Dec 22	36.02
Dec 22	43.64
Nov 22	44.7
Nov 22	40.23
Nov 22	7.06
Nov 22	15.66
Oct 22	15.84
Oct 22	14.78
Oct 22	16.17
Oct 22	17.47
Sep 22	20.54
Sep 22	19.52
Sep 22	19
Sep 22	17.66
Sep 22	15.57
Aug 22	18.12
Aug 22	17.56
Aug 22	8.8
Aug 22	7.47
Jul 22	6.44
Jul 22	6.61
Jul 22	6.64
Jul 22	7.07
Jul 22	6.92
Jun 22	6.84
Jun 22	7.27
Jun 22	7.44
Jun 22	7.6
May 22	7.5
May 22	7.27
May 22	5.1
May 22	5.71
Apr 22	5.63
Apr 22	5.8
Apr 22	5.91
Apr 22	6.76
Apr 22	6.21
Mar 22	4.92
Mar 22	4.92
Mar 22	4.52
Mar 22	4.31
Feb 22	4.43
Feb 22	4.65
Feb 22	4.66
Feb 22	4.53
Jan 22	4.47
Jan 22	4.52
Jan 22	5.17
Jan 22	5.45
Dec 21	5.83
Dec 21	5.42
Dec 21	5
Dec 21	4.98
Dec 21	4.85
Nov 21	5.45
Nov 21	4.24
Nov 21	3.57
Nov 21	3.63
Oct 21	3.48
Oct 21	3.71
Oct 21	3.71
Oct 21	3.76
Oct 21	3.92
Sep 21	4.06
Sep 21	4.25
Sep 21	3.95
Sep 21	4.16
Aug 21	4.25
Aug 21	3.95
Aug 21	4.43
Aug 21	4.77
Jul 21	3.98
Jul 21	3.35
Jul 21	3.3
Jul 21	3.44
Jul 21	3.69
Jun 21	3.96
Jun 21	3.86
Jun 21	3.91
Jun 21	3.58
May 21	3.54
May 21	3.47
May 21	3.34
May 21	3.13
Apr 21	3.43

No video analysis for this stock yet. Request one from our team.

News: BCLI

prnewswire.com · 24 Aug 2026

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.

prnewswire.com · 14 Aug 2026

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.

prnewswire.com · 28 Jul 2026

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidate NEW YORK, July 28, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced a major strategic expansion of its executive leadership team.